The global topiramate market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Topiramate is a medicine which is used for the treatment of epilepsy and is also referred to as anti-epileptic medicines. Antiepileptic drugs (AED) are generally used for neurologic and psychiatric purposes. The primary indication for this family of drugs is treating seizure disorders. Topiramate is only available on prescription and it can also be taken to prevent migraine. Increasing prevalence of epilepsy and migraine across the globe is expected to surge the demand for topiramate globally.
According to the World Health Organization (WHO) epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. As of 2019, nearly 50 million people across the globe had epilepsy. This makes epilepsy one of the most common neurological diseases globally. Moreover, as per the WHO, it is also estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. The risk of premature mortalities in people with epilepsy is up to three times higher than general population. Growing number of migraine cases is also surging the demand for topiramate across the globe.
To Request a Sample of our Report on Topiramate Market: https://www.omrglobal.com/request-sample/topiramate-market
Some key players operating in the market include Aurobindo Pharma Ltd., Johnson & Johnson Services, Inc., and Pfizer Inc., among others. The market players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in November 2021, Eton Pharmaceuticals Inc. and Azurity Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) approval of EPRONTIA (topiramate) oral solution, 25mg/mL. EPRONTIA has been approved as a monotherapy for treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; an adjunctive therapy for treatment of partial-onset seizures, primary generalized tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older; and as a preventive treatment of migraine in patients 12 years of age and older.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Product
- By Application
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Aurobindo Pharma Ltd., Johnson & Johnson Services, Inc., and Pfizer Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of Topiramate Market is Available @ https://www.omrglobal.com/industry-reports/topiramate-market
Global Topiramate Market Report by Segment
By Product
- 0.98
- 0.99
- Others
By Application
- Anticonvulsant
- Antimigraine
- Others
Global Topiramate Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
